Table 2.
Sample characteristics of cancer survivors completing the validation survey
| Characteristic | Mean (SD)/Range/Count |
|---|---|
| Age (years) | M = 44.39 years (SD = 15.02, Min = 18, Max = 81) |
| Sex at Birth | |
| Male | 132 (26.9%) |
| Female | 359 (73.1%) |
| Ethnicity | |
| Caucasian | 290 (59.1%) |
| African/African American | 152 (31.0%) |
| Asian | 17 (3.5%) |
| Hispanic or Latino | 12 (2.4%) |
| Native American / American Indian | 3 (0.6%) |
| Other | 17 (3.5%) |
| Primary Cancer Type(s) | |
| Breast | 169 (34.4%) |
| Prostate | 22 (4.5%) |
| Bowel/Colorectal | 32 (6.5%) |
| Melanoma | 18 (3.7%) |
| Lung | 26 (5.3%) |
| Lymphoma | 39 (7.9%) |
| Leukaemia | 28 (5.7%) |
| Brain | 14 (2.9%) |
| Pancreatic | 3 (0.6%) |
| Myeloma | 3 (0.6%) |
| Cervical | 21 (4.3%) |
| Thyroid | 30 (6.1%) |
| Testicular | 17 (3.5%) |
| Uterine | 14 (2.9%) |
| Ovarian | 19 (3.9%) |
| Sarcoma | 5 (1.0%) |
| Kidney | 5 (1.0%) |
| Bladder | 4 (0.8%) |
| Other | 22 (4.5%) |
| Five Most Common Country of Residence | |
| USA | 175 (35.6%) |
| South Africa | 119 (24.2%) |
| UK | 113 (23.0%) |
| Australia | 15 (3.1%) |
| Poland | 10 (2.0%) |
| Treatments Received | |
| Chemotherapy | 336 (68.4%) |
| Radiation | 256 (52.1%) |
| Hormone treatment | 133 (27.1%) |
| Targeted Therapies | 66 (13.4%) |
| Surgery | 110 (22.4%) |
| Immunotherapy | 78 (15.9%) |
| Other | 11 (2.2%) |
Rounding my result in percentages not equalling 100%